Insights

Strategic Focus Sumitomo Dainippon Pharma Oncology (SMP Oncology) emphasizes transformative cancer therapeutics with a global footprint in the US and Japan, signaling opportunities for co-development, licensing, or strategic collaborations in oncology pipelines and translational research.

Global footprint With teams in Lehi, Utah; Cambridge, MA; Tokyo and Osaka, SMP Oncology presents access to US and Japanese markets, enabling cross-border partnerships, regional clinical trials, and commercialization collaborations to accelerate product reach.

Data and Tech enablement Leveraging Databricks, Power BI, AWS, Salesforce, NetSuite and IBM SPSS indicates a mature data and CRM stack, suggesting opportunities for analytics-driven partnerships, real-world evidence studies, and joint data-driven market access strategies.

Innovation momentum Recent news highlights DSP-3077 development collaboration and translational data presentations at EHA 2026, signaling a pipeline open to partnerships in retinal therapies, hematology, and novel target spaces for co-development and funding.

Commercial potential Current revenue range and active oncology focus imply readiness for early-stage to mid-stage collaboration, including co-development, manufacturing partnerships, or licensing deals to expand portfolio and accelerate time-to-market.

Similar companies to Sumitomo Dainippon Pharma Oncology

Novartis Oncology
1.6K$1B - $10B
Takeda Oncology
1.6K$1B - $10B

Sumitomo Dainippon Pharma Oncology Tech Stack

Sumitomo Dainippon Pharma Oncology uses 8 technology products and services including Databricks, Power BI, Amazon Web Services, and more. Explore Sumitomo Dainippon Pharma Oncology's tech stack below.

Databricks
Big Data Processing
Power BI
Business Intelligence
Amazon Web Services
Cloud Hosting
Salesforce
Customer Relationship Management
NetSuite
E-commerce
IBM SPSS
Enterprise
Microsoft Intune
Enterprise Mobility Management
Atlassian Jira
Issue Trackers

Media & News

Sumitomo Dainippon Pharma Oncology's Email Address Formats

Sumitomo Dainippon Pharma Oncology uses at least 3 email formats:

Sumitomo Dainippon Pharma Oncology Email Formats	Example	Percentage
FLast@bostonbiomedical.com	JDoe@bostonbiomedical.com	88%
LFirst@bostonbiomedical.com	DJohn@bostonbiomedical.com	12%
F.Last@sumitomo-pharma.com	J.Doe@sumitomo-pharma.com	100%

Frequently Asked Questions

What is Sumitomo Dainippon Pharma Oncology's official website and social media links?

Sumitomo Dainippon Pharma Oncology's official website is sumitomo-pharma.com and has social profiles on LinkedIn.

How much revenue does Sumitomo Dainippon Pharma Oncology generate?

As of July 2026, Sumitomo Dainippon Pharma Oncology's annual revenue is estimated to be $10M - $25M.

What is Sumitomo Dainippon Pharma Oncology's NAICS code?

Sumitomo Dainippon Pharma Oncology's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Sumitomo Dainippon Pharma Oncology have currently?

As of July 2026, Sumitomo Dainippon Pharma Oncology has approximately 201 employees across 3 continents, including North America, Asia and Europe. Key team members include Vice President Drug Safety & Pharmacovigilance: H. S., President&ceo: M. T. and Head Of Ip Portfolio Management: T. R. Explore Sumitomo Dainippon Pharma Oncology's employee directory with LeadIQ.

What industry does Sumitomo Dainippon Pharma Oncology belong to?

Sumitomo Dainippon Pharma Oncology operates in the Pharmaceutical Manufacturing industry.

What technology does Sumitomo Dainippon Pharma Oncology use?

Sumitomo Dainippon Pharma Oncology's tech stack includes Databricks, Power BI, Amazon Web Services, Salesforce, NetSuite, IBM SPSS, Microsoft Intune and Atlassian Jira.

What is Sumitomo Dainippon Pharma Oncology's email format?

Sumitomo Dainippon Pharma Oncology's email format typically follows the pattern of FLast@bostonbiomedical.com. Find more Sumitomo Dainippon Pharma Oncology email formats with LeadIQ.

When was Sumitomo Dainippon Pharma Oncology founded?

Sumitomo Dainippon Pharma Oncology was founded in 2020.

Sumitomo Dainippon Pharma Oncology

Q: What technology does Sumitomo Dainippon Pharma Oncology use?

Sumitomo Dainippon Pharma Oncology's tech stack includes Linux, SAP Materials Management, SAP Business Technology Platform, LinkedIn, GPT-3.

Q: What is Sumitomo Dainippon Pharma Oncology's NAICS code?

Sumitomo Dainippon Pharma Oncology's NAICS code is 3254 (Pharmaceutical and Medicine Manufacturing).

Pharmaceutical ManufacturingMassachusetts, United States201-500 Employees

Sumitomo Dainippon Pharma Oncology is the U.S.-based oncology subsidiary of Sumitomo Pharma Co., Ltd., dedicated to developing novel cancer therapeutics. The organization coordinates discovery research, external innovation, clinical development and commercialization across its teams in Cambridge, Massachusetts; Lehi, Utah; and in Tokyo and Osaka, Japan. Its Cambridge site at 640 Memorial Drive anchors part of its U.S. operations. 

The company's pipeline targets oncogenic pathways, survival mechanisms and novel protein interactions to address unmet clinical needs in oncology. Recent activity in 2026 includes SMPA presenting clinical and translational data at the EHA conference on investigational therapy for relapsed/refractory myelofibrosis and on menin inhibition in leukemia.